Maher Masoud Purchases 75,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT) CEO Maher Masoud purchased 75,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 13th. The stock was acquired at an average cost of $1.37 per share, with a total value of $102,750.00. Following the completion of the acquisition, the chief executive officer directly owned 175,000 shares of the company’s stock, valued at $239,750. The trade was a 75.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

MaxCyte Trading Down 3.5%

Shares of NASDAQ:MXCT opened at $1.36 on Friday. MaxCyte, Inc. has a 1-year low of $1.26 and a 1-year high of $5.20. The stock has a market capitalization of $144.99 million, a P/E ratio of -3.16 and a beta of 1.23. The business has a 50-day moving average price of $2.07 and a two-hundred day moving average price of $2.70.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The business had revenue of $8.51 million for the quarter, compared to analyst estimates of $9.57 million. MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%. As a group, equities analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current year.

Analysts Set New Price Targets

MXCT has been the subject of several research reports. William Blair cut shares of MaxCyte from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 7th. BTIG Research reissued a “neutral” rating on shares of MaxCyte in a research note on Monday, August 11th. Stephens initiated coverage on shares of MaxCyte in a report on Tuesday, July 22nd. They issued an “overweight” rating and a $6.00 price target for the company. Finally, Wall Street Zen cut shares of MaxCyte from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $7.00.

Institutional Trading of MaxCyte

A number of institutional investors have recently bought and sold shares of MXCT. Lazard Asset Management LLC lifted its stake in shares of MaxCyte by 94.2% in the 2nd quarter. Lazard Asset Management LLC now owns 284,498 shares of the company’s stock valued at $620,000 after purchasing an additional 137,983 shares during the period. BNP Paribas Financial Markets increased its holdings in MaxCyte by 266.6% in the second quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after purchasing an additional 18,913 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in MaxCyte in the second quarter valued at about $272,000. Bank of America Corp DE boosted its holdings in MaxCyte by 54.1% during the second quarter. Bank of America Corp DE now owns 84,836 shares of the company’s stock worth $185,000 after buying an additional 29,771 shares during the last quarter. Finally, AXA S.A. boosted its holdings in MaxCyte by 123.2% during the second quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after buying an additional 1,215,481 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.